Skip to main content

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade)

2026-09-02
ADMA Biologics stock is downgraded to Hold as FY26 guidance drops and growth slows. See ADMA's ASCENIV outlook, BIVIGAM decline, and $9.52 DCF.

IHF: Healthcare Dashboard For August

2026-08-16
Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.

ADMA Biologics: The Earnings Reset Still Leaves More Upside

2026-08-12
ADMA Biologics faces a lower earnings base after some challenging times, but ASCENIV remains its key growth driver. Read more on what could be next for this biotech.

ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

2026-08-06
ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...

2026-08-06
ADMA Biologics Inc (ADMA) delivers strong Q2 2026 results with record Ascentiv growth and robust cash generation, despite persistent competitive pressures in the standard IG market.

ADMA Biologics (NASDAQ:ADMA) Shares Slide as Q2 Results Miss Estimates

2026-08-05
ADMA Biologics Q2 misses estimates, shares dip; ASCENIV surges 24% but BIVIGAM drags results.

ADMA Biologics Q2 Earnings Call Highlights

2026-08-05
ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The company reiterated its full-year financial outlook and said it remains on track to meet or exceed

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-08-05
2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue 2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year 2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year 2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year 2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Yea

ADMA Biologics, Inc. (ADMA) Q2 2026 Earnings Call Transcript

2026-08-05
ADMA Biologics, Inc. (ADMA) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsAdam Grossman - Co-Founder, President, CEO & DirectorP.

ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est

2026-08-05
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.